Tamoxifen in the treatment of luminal breast cancer. Implications of active metabolites on gene expression, side effects and clinical outcome

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Unknown venue

• Publication date

  2019-02-21

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• EMP1 regulates caspase-9 and VEGFC expression and suppresses prostate cancer cell proliferation and invasion

  2014cited by this paper
• Aberrant expression of CXCR4 significantly contributes to metastasis and predicts poor clinical outcome in breast cancer.

  2014cited by this paper
• Inferring alterations in cell‐to‐cell communication in HER2+ breast cancer using secretome profiling of three cell models

  2014cited by this paper
• Downregulation of Steroid Receptor Coactivator-2 Modulates Estrogen-Responsive Genes and Stimulates Proliferation of MCF-7 Breast Cancer Cells

  2013cited by this paper
• Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts

  2013cited by this paper
• Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment

  2013influential reference
• Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens

  2013cited by this paper
• Clinical and biomarker predictors of side effects from tamoxifen

  2012cited by this paper
• PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees

  2012cited by this paper
• Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.

  2011cited by this paper
• The Kinase SGK1 in the Endoderm and Mesoderm Promotes Ectodermal Survival by Down-Regulating Components of the Death-Inducing Signaling Complex

  2011cited by this paper
• Orally administered Endoxifen is a new therapeutic agent for breast cancer

  2010cited by this paper
• Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells

  2010cited by this paper
• Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry.

  2010cited by this paper
• Tumorigenesis and Neoplastic Progression Overexpression of Galectin-7 , A Myoepithelial Cell Marker , Enhances Spontaneous Metastasis of Breast Cancer Cells

  2010cited by this paper
• Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia

  2009influential reference
• The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?

  2008cited by this paper
• The human keratins: biology and pathology

  2008cited by this paper
• Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer Cells

  2006cited by this paper
• Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation

  2006cited by this paper
• Keratin 6 is not essential for mammary gland development

  2006cited by this paper
• Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial

  2004cited by this paper
• ACTR/AIB1 Functions as an E2F1 Coactivator To Promote Breast Cancer Cell Proliferation and Antiestrogen Resistance

  2004cited by this paper
• HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway

  2004cited by this paper
• Association of Tamoxifen (TAM) and TAM Metabolite Concentrations with Self-Reported Side Effects of TAM in Women with Breast Cancer

  2004cited by this paper
• Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator

  2004cited by this paper
• A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

  2003cited by this paper
• Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue

  2001cited by this paper
• Correspondence analysis applied to microarray data

  2001cited by this paper
• Eye problems in breast cancer patients treated with tamoxifen

  2000cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Basic guide to the mechanisms of antiestrogen action.

  1998cited by this paper
• AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.

  1997cited by this paper
• Age‐related difference in tamoxifen disposition

  1996cited by this paper
• Tamoxifen-associated eye disease. A review.

  1996cited by this paper
• Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.

  1991cited by this paper
• Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.

  1990cited by this paper
• Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.

  1989cited by this paper
• Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.

  1984cited by this paper
• N-desmethyltamoxifen inhibits growth of MCF 7 human mammary carcinoma cells in vitro.

  1983cited by this paper
• Antiestrogen basicity--activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity.

  1982cited by this paper
• Binding of [3H]monohydroxytamoxifen by immature rat tissues in vivo.

  1982cited by this paper
• Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues.

  1981cited by this paper
• A human cell line from a pleural effusion derived from a breast carcinoma.

  1973cited by this paper

• Tamoxifen and the Risk of Breast Cancer in Women With Different Types of Mutation

  2025influential citation